Ulf is co-founder and since 2022 CEO and Board member of T-CURX, a German CAR-T cell company, spun-out from University Clinics, Würzburg. T-CURX is focused on developing and clinically validating next-generation CAR-T therapies based on non-viral CAR-T manufacturing developed in the lab of T-CURX co-founder, Prof. Michael Hudecek at University Clinics, Würzburg. Previously, Ulf was co-founder, CEO and Board member of NBE-Therapeutics, a Swiss Biotech company, focused on the development of ADCs, until the trade-sale of NBE to Boehringer Ingelheim in 2021 for $ 1.4 bn. Before that Ulf had co-founded 4-Antibody, a Swiss Biotech company, which was sold to U.S.-based AgenusBio in 2012. Ulf is an Immunologist by training with a PhD in Immunology for work performed at the Basel Institute for Immunology, a triple-nobel prize awarded former research institute supported by Roche.

Ulf is also Managing Director of Viopas Venture Consulting (www.viopasventure.ch), Basel, Switzerland, and independent Board member of HKEX-listed public company WuXiXDC (https://wuxixdc.com/) and NASDAQ-listed company Adagene (https://www.adagene.com/). Ulf also holds a diploma in Technology Entrepreneurship from the Executive School of Management, Technology and Law of the University St. Gallen, Switzerland (www.es.unisg.ch).